➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
Dow
Express Scripts
Moodys

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

CITALOPRAM HYDROBROMIDE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Citalopram Hydrobromide patents expire, and what generic alternatives are available?

Citalopram Hydrobromide is a drug marketed by Mylan Pharms Inc, Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Hikma, Lannett Co Inc, Pharm Assoc, Biovail Labs Intl, Amneal Pharms Ny, Apotex Inc, Aurobindo, Chartwell Molecular, Cosette, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Fosun Pharma, Glenmark Generics, Heritage Pharma, Invagen Pharms, Jubilant Generics, Mylan, Natco Pharma Ltd, Roxane, Sun Pharm Inds Inc, Sun Pharm Industries, Taro, Torpharm, and Torrent Pharms. and is included in thirty-three NDAs.

The generic ingredient in CITALOPRAM HYDROBROMIDE is citalopram hydrobromide. There are fifty-six drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the citalopram hydrobromide profile page.

US ANDA Litigation and Generic Entry Outlook for Citalopram Hydrobromide

A generic version of CITALOPRAM HYDROBROMIDE was approved as citalopram hydrobromide by AUROBINDO on October 28th, 2004.

  Start Trial

Drug patent expirations by year for CITALOPRAM HYDROBROMIDE
Drug Prices for CITALOPRAM HYDROBROMIDE

See drug prices for CITALOPRAM HYDROBROMIDE

Drug Sales Revenue Trends for CITALOPRAM HYDROBROMIDE

See drug sales revenues for CITALOPRAM HYDROBROMIDE

Recent Clinical Trials for CITALOPRAM HYDROBROMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3
Haining Health-Coming Biotech Co., Ltd.Phase 2
University of PittsburghN/A

See all CITALOPRAM HYDROBROMIDE clinical trials

Pharmacology for CITALOPRAM HYDROBROMIDE
Medical Subject Heading (MeSH) Categories for CITALOPRAM HYDROBROMIDE

US Patents and Regulatory Information for CITALOPRAM HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roxane CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077041-001 Nov 23, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Glenmark Generics CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077654-002 Feb 27, 2009 AB RX No No   Start Trial   Start Trial   Start Trial
Epic Pharma Llc CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077036-002 Oct 28, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Torrent Pharms CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 078216-001 Mar 27, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
Dow
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.